Cempra Pharmaceuticals (Chapel Hill, NC) a clinical-stage company developing antibiotics for difficult-to-treat and drug-resistant infections, closed a $46M Series C financing. Participants include Quaker BioVentures, Devon Park Bioventures, Aisling Capital, Intersouth Partners, Teachers’ Private Capital and I. Wistar Morris III.